Antibodies to IL-6 and use thereof

• US 9,884,912 B2
• Filed: 11/18/2014
• Issued: 02/06/2018
• Est. Priority Date: 05/21/2007
• Status: Expired due to Fees

• Current Assignee: Vitaeris Inc. (CSL Limited)
• Original Assignee: AlderBio Holdings, LLC (Lundbeck Foundation)
• Inventors: Garcia-Martinez, Leon F., Carvalho Jensen, Anne Elisabeth, Anderson, Katie Olson, Dutzar, Benjamin H., Ojala, Ethan Wayne, Kovacevich, Brian R., Latham, John A., Smith, Jeffrey T. L.
• Primary Examiner(s): Allen, Marianne P
• Application Number:
  US14/546,074
• Publication Number:
  US 20150132224A1
• Time in Patent Office: 1,176 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/51 Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/515 Complete light chain, i.e. VL + CL
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/64 comprising a combination of variable region and constant region components
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V_H, V_L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Claims

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a heavy chain polypeptide or variable heavy chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:

2, 20, 702, 706 and 709; and

a nucleic acid sequence encoding a light chain polypeptide or variable light chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS;

3, 18, 19, 657, 658, 704 and 708.

2. The polynucleotide of claim 1 where yeast or human preferred codons are used.

3. A vector comprising the isolated polynucleotide of claim 1.

4. A recombinant cell which comprises the isolated polynucleotide of claim 1.

5. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:

701 or SEQ ID NO;

705 and the heavy chain polypeptide is encoded by SEQ ID NO;

703 or 707.

6. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:

701 and the heavy chain polypeptide is encoded by SEQ ID NO;

703.

7. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:

705 and the heavy chain polypeptide is encoded by SEQ ID NO;

707.

8. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:

705 and the heavy chain polypeptide is encoded by SEQ ID NO;

703.

9. The isolated polynucleotide of claim 1 where the light chain polypeptide is encoded by SEQ ID NO:

701 and the heavy chain polypeptide is encoded by SEQ ID NO;

707.

10. An isolated polynucleotide comprising a nucleic acid sequence encoding an amino acid sequence selected from SEQ ID NOS:

2, 3, 18, 19, 20, 702, 704, 706, 708 and 709.

11. The isolated polynucleotide of claim 10 where yeast or human preferred codons are used.

12. A vector comprising the isolated polynucleotide of claim 10.

13. A recombinant cell comprising the isolated polynucleotide of claim 10.